SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ventorp Filip)
 

Sökning: WFRF:(Ventorp Filip) > (2020-2024) > Add-on pramipexole ...

  • Lindahl, JesperLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Enheten för Biologisk Psykiatri och Precisionspsykiatri,Forskargrupper vid Lunds universitet,Department of Clinical Sciences, Lund,Faculty of Medicine,Unit for Biological and Precision Psychiatry,Lund University Research Groups,Skåne University Hospital (författare)

Add-on pramipexole for anhedonic depression : study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • BMJ Publishing Group,2023
  • 9
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:researchportal.hkr.se/admin:publications/7ed5d143-f92d-4eb5-a554-15df7809e611
  • oai:researchportal.hkr.se/admin:publications/7ed5d143-f92d-4eb5-a554-15df7809e611URI
  • https://doi.org/10.1136/bmjopen-2023-076900DOI
  • https://lup.lub.lu.se/record/93bc3bfa-d802-4d80-ae47-5cd0457b2cf3URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:svenska &engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Publisher Copyright: © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
  • INTRODUCTION: Many depressed patients do not achieve remission with available treatments. Anhedonia is a common residual symptom associated with treatment resistance as well as low function and quality of life. There are currently no specific and effective treatments for anhedonia. Some trials have shown that dopamine agonist pramipexole is efficacious for treating depression, but more data is needed before it could become ready for clinical prime time. Given its mechanism of action, pramipexole might be a useful treatment for a depression subtype characterised by significant anhedonia and lack of motivation-symptoms associated with dopaminergic hypofunction. We recently showed, in an open-label pilot study, that add-on pramipexole is a feasible treatment for depression with significant anhedonia, and that pramipexole increases reward-related activity in the ventral striatum. We will now confirm or refute these preliminary results in a randomised controlled trial (RCT) and an open-label follow-up study. METHODS AND ANALYSIS: Eighty patients with major depression (bipolar or unipolar) or dysthymia and significant anhedonia according to the Snaith Hamilton Pleasure Scale (SHAPS) are randomised to either add-on pramipexole or placebo for 9 weeks. Change in anhedonia symptoms per the SHAPS is the primary outcome, and secondary outcomes include change in core depressive symptoms, apathy, sleep problems, life quality, anxiety and side effects. Accelerometers are used to assess treatment-associated changes in physical activity and sleep patterns. Blood and brain biomarkers are investigated as treatment predictors and to establish target engagement. After the RCT phase, patients continue with open-label treatment in a 6-month follow-up study aiming to assess long-term efficacy and tolerability of pramipexole. ETHICS AND DISSEMINATION: The study has been approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. The study is externally monitored according to Good Clinical Practice guidelines. Results will be disseminated via conference presentations and peer-reviewed publications. TRIAL REGISTRATION NUMBER: NCT05355337 and NCT05825235.
  • Introduction Many depressed patients do not achieve remission with available treatments. Anhedonia is a common residual symptom associated with treatment resistance as well as low function and quality of life. There are currently no specific and effective treatments for anhedonia. Some trials have shown that dopamine agonist pramipexole is efficacious for treating depression, but more data is needed before it could become ready for clinical prime time. Given its mechanism of action, pramipexole might be a useful treatment for a depression subtype characterised by significant anhedonia and lack of motivation—symptoms associated with dopaminergic hypofunction. We recently showed, in an open-label pilot study, that add-on pramipexole is a feasible treatment for depression with significant anhedonia, and that pramipexole increases reward-related activity in the ventral striatum. We will now confirm or refute these preliminary results in a randomised controlled trial (RCT) and an open-label follow-up study. Methods and analysis Eighty patients with major depression (bipolar or unipolar) or dysthymia and significant anhedonia according to the Snaith Hamilton Pleasure Scale (SHAPS) are randomised to either add-on pramipexole or placebo for 9 weeks. Change in anhedonia symptoms per the SHAPS is the primary outcome, and secondary outcomes include change in core depressive symptoms, apathy, sleep problems, life quality, anxiety and side effects. Accelerometers are used to assess treatment-associated changes in physical activity and sleep patterns. Blood and brain biomarkers are investigated as treatment predictors and to establish target engagement. After the RCT phase, patients continue with open-label treatment in a 6-month follow-up study aiming to assess long-term efficacy and tolerability of pramipexole. Ethics and dissemination The study has been approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. The study is externally monitored according to Good Clinical Practice guidelines. Results will be disseminated via conference presentations and peer-reviewed publications.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Asp, MarieLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Enheten för Biologisk Psykiatri och Precisionspsykiatri,Forskargrupper vid Lunds universitet,Department of Clinical Sciences, Lund,Faculty of Medicine,Unit for Biological and Precision Psychiatry,Lund University Research Groups,Skåne University Hospital(Swepub:lu)med-ma10 (författare)
  • Ståhl, DaryaLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Enheten för Biologisk Psykiatri och Precisionspsykiatri,Forskargrupper vid Lunds universitet,Department of Clinical Sciences, Lund,Faculty of Medicine,Unit for Biological and Precision Psychiatry,Lund University Research Groups(Swepub:lu)da6801ty (författare)
  • Tjernberg, JohannaLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Enheten för Biologisk Psykiatri och Precisionspsykiatri,Forskargrupper vid Lunds universitet,Department of Clinical Sciences, Lund,Faculty of Medicine,Unit for Biological and Precision Psychiatry,Lund University Research Groups,Region Skåne(Swepub:lu)jo0167tj (författare)
  • Eklund, MoaLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Enheten för Biologisk Psykiatri och Precisionspsykiatri,Forskargrupper vid Lunds universitet,Department of Clinical Sciences, Lund,Faculty of Medicine,Unit for Biological and Precision Psychiatry,Lund University Research Groups,Skåne University Hospital(Swepub:lu)mo0741ek (författare)
  • Björkstrand, JohannesLund University,Lunds universitet,Institutionen för psykologi,Samhällsvetenskapliga institutioner och centrumbildningar,Samhällsvetenskapliga fakulteten,Department of Psychology,Departments of Administrative, Economic and Social Sciences,Faculty of Social Sciences(Swepub:lu)jo2676bj (författare)
  • van Westen, DanielleLund University,Lunds universitet,Diagnostisk radiologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Diagnostic Radiology, (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)ront-dva (författare)
  • Jensen, JimmyKristianstad University(Swepub:lu)extLU-899 (författare)
  • Månsson, KristofferKarolinska Institute (författare)
  • Tornberg, ÅsaLund University,Lunds universitet,Institutionen för hälsovetenskaper,Medicinska fakulteten,Barns och familjers hälsa,Forskargrupper vid Lunds universitet,Department of Health Sciences,Faculty of Medicine,Child and Family Health,Lund University Research Groups(Swepub:lu)fhv-ase (författare)
  • Svensson, MartinaLund University,Lunds universitet,Institutionen för experimentell medicinsk vetenskap,Medicinska fakulteten,Neuroinflammation,Forskargrupper vid Lunds universitet,Department of Experimental Medical Science,Faculty of Medicine,Lund University Research Groups(Swepub:lu)med-ms17 (författare)
  • Deierborg, TomasLund University,Lunds universitet,Institutionen för experimentell medicinsk vetenskap,Medicinska fakulteten,Neuroinflammation,Forskargrupper vid Lunds universitet,Department of Experimental Medical Science,Faculty of Medicine,Lund University Research Groups(Swepub:lu)expb-tol (författare)
  • Ventorp, FilipLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Enheten för Biologisk Psykiatri och Precisionspsykiatri,Forskargrupper vid Lunds universitet,Department of Clinical Sciences, Lund,Faculty of Medicine,Unit for Biological and Precision Psychiatry,Lund University Research Groups,Skåne University Hospital(Swepub:lu)med-fve (författare)
  • Lindqvist, DanielLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Enheten för Biologisk Psykiatri och Precisionspsykiatri,Forskargrupper vid Lunds universitet,Department of Clinical Sciences, Lund,Faculty of Medicine,Unit for Biological and Precision Psychiatry,Lund University Research Groups,Region Skåne(Swepub:lu)med-del (författare)
  • Institutionen för kliniska vetenskaper, LundMedicinska fakulteten (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:BMJ Open: BMJ Publishing Group13:11, s. 92044-6055

Internetlänk

Hitta via bibliotek

  • BMJ Open (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy